Semaglutide vs Tirzepatide
Updated: April 25, 2026
Comparing two major incretin-based peptides in metabolic research, with emphasis on mechanism, clinical outcomes, and how their handling evidence differs.
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Mechanism | Selective GLP-1 Receptor Agonist | Dual GLP-1 and GIP Receptor Agonist |
| PeptideClock Handling Profile | More handling-tolerant in the current model | More handling-sensitive in the current model |
| In-Use Stability | 56 days after first use (at room temp or refrigerated) [FDA label] | 21 days at room temp after first use; refrigerate until expiration (unopened) [FDA label] |
| Clinical Weight Loss | ~14.9% (STEP trials) | ~20.9% (SURMOUNT-1, 15 mg dose; ~15-20.9% across doses) |
| Typical Frequency | Once Weekly | Once Weekly |
Key Differences for Researchers
While both peptides target the GLP-1 receptor, Tirzepatide is unique because it also targets the glucose-dependent insulinotropic polypeptide (GIP) receptor. In head-to-head clinical trials of the regulated products, this dual-action approach was associated with greater weight loss and glycemic control than the GLP-1-only comparator.
From a handling-stability perspective, PeptideClock currently treats semaglutide as the more handling-tolerant of the two. That reflects a mix of label-backed product stability and the site's conservative model choices, not a universal claim that every reconstituted semaglutide vial outperforms every tirzepatide workflow in real-world use.
Clinical Trial Snapshot
- Semaglutide: Strong outcomes in STEP trials with robust long-term metabolic trend data.
- Tirzepatide: Strong outcomes in SURMOUNT trials with dual-pathway impact.
Key references:STEP-1 (Wilding et al., N Engl J Med 2021, PMID 33567185) — semaglutide 2.4mg: −14.9% body weight at 68 weeks.SURMOUNT-1 (Jastreboff et al., N Engl J Med 2022, PMID 35658024) — tirzepatide 15mg: −20.9% body weight at 72 weeks (range −16.0% to −22.5% across doses).
Side-Effect Profile (Research Context)
Both compounds commonly report GI-related tolerability considerations in escalation phases. Protocols should prioritize gradual titration logic and consistent monitoring.
Dosing Protocol Comparison
Both are frequently modeled as weekly protocols, but implementation details depend on concentration setup, handling consistency, and objective selection.
Cost & Access Considerations
Cost variability is highly source- and market-dependent. Comparison decisions should be made with quality controls and stability handling costs included, not vial price alone.